证券代码：301267 证券简称：华厦眼科 公告编号：2025-036 华厦眼科医院集团股份有限公司 2025 年中期分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指 引第 9 号——回购股份》等相关规定，华厦眼科医院集团股份有限公司（以下简 称"公司"或"本公司"）回购专用账户中的股份不参与本次分红派息。公司 2025 年中期分红派息以当前总股本 840,000,000 股剔除已回购股份 7,527,840 股 后的 832,472,160 股为基数，向全体股东每 10 股派发现金红利人民币 0.90 元（含 税），合计派发现金红利 74,922,494.40 元。 2、本次分红派息实施后计算除权除息价格时，以公司总股本（含回购股份， 即 840,000,000 股）折算后的每 10 股现金红利（含税）=现金分红总额/总股本（含 回购股份）*10=74,922,494.40 元/840,000,000 股*10=0.891934 元（保留六位小数， 最后一位直接截 ...

12月4日，华厦眼科医院集团战略与学术研讨会在厦门盛大召开。中国工程院院士谢立信教授，中华医 学会眼科学分会名誉主委、华厦眼科医院集团战略与学术委员会主委葛坚教授，国际眼科科学院院士、 厦门眼科中心总院长黎晓新教授，国际眼科科学院院士、华厦眼科医院集团专家委员会主席赵堪兴教 授，中华医学会眼科学分会候任主委、华厦眼科医院集团科技创新委员会主席孙兴怀教授，国际眼科科 学院院士、华厦眼科医院集团学科建设委员会主委刘祖国教授，中华医学会眼科学分会副主委杨培增教 授、许迅教授，山东省眼科医院院长史伟云教授，全军眼科专业委员会主委叶剑教授，北京大学人民医 院眼科主任赵明威教授，中山大学中山眼科中心副主任梁凌毅教授，复旦大学附属眼耳鼻喉科医院眼科 研究院副院长赵晨教授，解放军总医院眼科医学部副主任王丽强教授，厦门大学医学院副院长李炜教 授，中华医学会中华眼科杂志黄翊彬教授，福建省医学会眼科学分会常务委员朱益华教授，上海交通大 学附属第一人民医院邵毅教授，华厦眼科医院集团王骞教授、吴国基教授、郭海科教授、王利华教授、 朱思泉教授、张明昌教授、吴护平教授、张广斌教授、潘美华教授、王玉宏教授、黄艳明教授等专家学 者出席会议。 ...

证券日报网讯12月4日，华厦眼科（301267）在互动平台回答投资者提问时表示，公司长期专注于眼科 医疗服务，已经建立了全国连锁运营的诊疗服务体系。公司正按照发展战略规划，通过自建及并购方 式，稳步推进全国医疗服务网络布局。 ...

Group 1 - The Shenzhen Stock Exchange announced a periodic adjustment of sample stocks for various indices, including the Shenzhen Component Index and the ChiNext Index, effective December 15, 2025 [1] - Huaxia Eye Hospital (301267) is one of the stocks being removed from the ChiNext Index sample list [1] Group 2 - Huaxia Eye Hospital was listed on the ChiNext on November 7, 2022, with an initial offering price of 50.88 RMB per share and is currently in a state of decline [2] - The total funds raised from the initial public offering amounted to 305.28 million RMB, with a net amount of 276.85 million RMB after deducting issuance costs [2] - The company originally planned to raise 77.85 million RMB for various projects, including hospital construction and operational upgrades, but ultimately raised 198.99 million RMB more than planned [2] Group 3 - In the 2022 annual shareholders' meeting held on May 15, 2023, the company approved a profit distribution plan, distributing a cash dividend of 2.8 RMB per 10 shares, totaling 15.68 million RMB [3] - The company also approved a capital reserve increase, converting 5 shares for every 10 shares held, increasing the total share capital from 56 million shares to 84 million shares [3] - Huaxia Eye Hospital Group was established in 2004 in Xiamen, Fujian Province, with a registered capital of 84 million RMB [3]

Investment Rating - The report does not explicitly state an investment rating for the ophthalmology industry Core Insights - The ophthalmology medical service market in China is experiencing stable growth, with the market size projected to reach CNY 2,521.5 billion by 2025, reflecting a compound annual growth rate (CAGR) of 16.0% from 2020 to 2025 [7][10] - The revenue structure of companies in the industry is diversifying, with a notable increase in the proportion of refractive and optical services, while the basic medical sector faces pressure from policy changes and demand structure [3][50] - The overall growth rate of ophthalmology hospitals is slowing, with private hospitals expected to increase to 3,044 by 2028, while public hospitals will only expand to 83 [10][11] Company Summaries - Aier Eye Hospital continues to lead the industry with a revenue of CNY 174.84 billion, showing a 7.3% year-on-year growth, demonstrating strong risk resistance [25][29] - Huaxia Eye Hospital reported a revenue of CNY 32.7 billion, with a slight increase of 2.8% year-on-year, while its net profit rose by 3% to CNY 4.3 billion [25][26] - Puri Eye Hospital achieved a revenue of CNY 22.01 billion, with a 3.0% increase, but its net profit saw a significant drop of 66.1% due to new hospital losses and high expenses [25][30] - He Eye Hospital's revenue decreased by 1.1% to CNY 8.6 billion, but its net profit surged by 232.2% to CNY 0.54 billion, benefiting from regional business optimization [25][30] - Xima Medical reported a revenue of CNY 8.6 billion in 2025H1, a 61.29% increase year-on-year, achieving breakeven in mainland China operations [41][41] Market Dynamics - The proportion of refractive income is increasing across companies, with Puri Eye Hospital leading at 49.34%, followed by Aier Eye Hospital at 40.13% [50][47] - The cataract income share is declining, particularly for Huaxia Eye Hospital, which dropped from 22.70% to 20.15% due to the impact of centralized procurement policies [50][51] - The report highlights a trend of increasing high-end surgical procedures, which is driving up average transaction prices in the industry [58]

Core Viewpoint - The report highlights the significant growth in the number of myopia patients in China, indicating a rising demand for ophthalmic medical services and a robust market potential for eye care due to increasing health awareness and an aging population [1] Industry Summary - The number of myopia patients in China increased from 540 million in 2016 to 660 million in 2020, with the national myopia prevalence rising from 39.2% to 47.1% [1] - The demand for refractive surgery is expected to grow continuously as awareness of vision health increases and the number of myopia patients rises [1] - The aging population and enhanced health consciousness among the elderly are projected to expand the demand for cataract and other eye disease treatments, indicating a vast market potential for ophthalmic medical services [1] Company Summary - Huaxia Eye Hospital is recognized as a leading private ophthalmic medical enterprise in China, with strong academic capabilities and a clear expansion model [1] - The company is expected to maintain steady growth in performance, driven by the anticipated recovery in consumer healthcare, continuous upgrades in refractive surgical techniques, and increased demand for medical services due to aging trends [1] - Projected net profits for Huaxia Eye Hospital are estimated to reach 482 million, 552 million, and 629 million yuan for the years 2025, 2026, and 2027, respectively [1]

Investment Rating - The report gives a "Recommended" rating for Huaxia Eye Hospital (301267.SZ) [1] Core Views - The demand for ophthalmic diagnosis and treatment is continuously growing, supported by favorable national policies for the development of private specialty hospitals. The number of myopia patients in China has increased from 540 million in 2016 to 660 million in 2020, with the incidence rate rising from 39.2% to 47.1% [6][24] - The company is successfully expanding its operations, with a decrease in the revenue contribution from its core hospital, Xiamen Eye Center, indicating successful new hospital openings and improved performance from other facilities [6][40] - The profitability of cataract and refractive surgery projects is recovering, with revenue growth in refractive services driven by technological upgrades [6][34] Summary by Sections 1. Company Overview - Huaxia Eye Hospital focuses on ophthalmic medical services and has expanded its chain operations nationwide, establishing a network of 64 specialized hospitals and 67 vision centers across 49 cities [9][15] 2. Market Demand and Policy Support - The demand for eye care services is on the rise, with significant growth in the elderly population and increasing awareness of eye health among the public. The aging population is expected to drive the demand for cataract surgeries and other eye-related treatments [24][26] - National policies are favorable for the development of private specialty hospitals, enhancing the overall healthcare service quality and expanding the market for ophthalmic services [29][30] 3. Business Segments Performance - The refractive surgery segment is the company's core business, contributing the highest revenue share and showing a recovery in profit margins due to new surgical techniques [18][34] - The cataract business faced short-term pressure due to national procurement policies but is expected to stabilize and grow in the long term as the aging population increases [31][43] - The integrated vision care project has shown steady revenue growth, although initial investments in new centers have impacted profit margins [38] 4. Financial Performance and Forecast - The company achieved a revenue of 40.13 billion yuan in 2023, with a year-on-year growth of 24.1%. However, growth slowed in 2024 due to high base effects, with revenue of 40.27 billion yuan, a mere 0.3% increase [5][20] - Profit forecasts for 2025, 2026, and 2027 are 4.82 billion yuan, 5.52 billion yuan, and 6.29 billion yuan respectively, indicating a positive outlook for sustained growth [6][43]

Group 1: Financial Performance - In the first three quarters of 2025, the company achieved operating revenue of 3.272 billion yuan, a year-on-year increase of 2.83% [1] - The net profit attributable to shareholders reached 434 million yuan, reflecting a year-on-year increase of 3.04% [1] - For the third quarter alone, the operating revenue was 1.133 billion yuan, showing a slight year-on-year growth of 0.13%, while the net profit attributable to shareholders decreased by 2.37% to 152 million yuan [1] Group 2: Dividend Distribution - The company plans to distribute a cash dividend of 0.9 yuan (including tax) for every 10 shares, totaling 749.2 million yuan, based on the number of shares after deducting the repurchased shares of 83.2 million [1] Group 3: Cost and Margin Analysis - The gross profit margin for the first three quarters of 2025 was 45.03%, a decrease of 1.00 percentage point year-on-year [1] - The selling expense ratio was 13.21%, down by 0.94 percentage points year-on-year, while the management expense ratio was 11.49%, a decrease of 0.08 percentage points [1] - The financial expense ratio increased by 0.24 percentage points to 1.03%, primarily due to reduced bank interest income from investing temporarily idle funds in financial products [1] Group 4: Strategic Development - The company is leveraging its "dual top-tier" advantage to establish a nationwide chain operation service system, focusing on both organic growth and external acquisitions [2] - In 2024, the company successfully acquired Chengdu Aidi Eye Hospital, becoming a large medical chain group with "dual top-tier" eye hospitals [2] - The company has identified 24 key investment provinces in China to build an ophthalmic medical service network through self-construction or acquisition [2] Group 5: Technological Advancement - The company introduced the new Zeiss SMILE pro technology for minimally invasive surgery, completing 2,000 SMILE pro surgeries by September 25, 2025, making it the first single hospital globally to reach this milestone in such a short time [2] Group 6: Revenue and Profit Forecast - The company forecasts operating revenues of 4.206 billion yuan, 4.697 billion yuan, and 5.239 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 4.4%, 11.7%, and 11.5% [2] - The net profit attributable to shareholders is expected to be 499 million yuan, 577 million yuan, and 661 million yuan for the same years, with growth rates of 16.4%, 15.6%, and 14.5% [2]

Investment Rating - The investment rating for the company is "Accumulate" [4][9]. Core Views - The company achieved a revenue of 3.272 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 2.83%, and a net profit attributable to the parent company of 434 million yuan, an increase of 3.04% year-on-year [1][4]. - The company plans to distribute a cash dividend of 0.9 yuan per 10 shares to all shareholders, totaling 74.92 million yuan [1][4]. - The company is focusing on expanding its national chain of ophthalmology services through both organic growth and acquisitions, having successfully acquired Chengdu Aidi Eye Hospital in 2024 [2][4]. - The introduction of new technologies, such as the Zeiss SMILE pro surgery, has positioned the company as a leader in the field, completing 2,000 surgeries in a record time [2][4]. Financial Performance Summary - For the first three quarters of 2025, the gross profit margin was 45.03%, a decrease of 1.00 percentage points year-on-year [1]. - The company forecasts revenue growth from 4.206 billion yuan in 2025 to 5.239 billion yuan in 2027, with corresponding net profits expected to rise from 499 million yuan to 661 million yuan during the same period [2][8]. - The projected earnings per share (EPS) for 2025 is 0.59 yuan, with a price-to-earnings (P/E) ratio of 33.9 [2][8].

Group 1 - The company, Huaxia Eye Hospital, is actively exploring the application and development of smart medical technologies and products in the field of ophthalmic medical services [1] - The current applications related to smart medical technologies are still in the gradual exploration phase [1] - Investors are advised to pay attention to investment risks associated with these developments [1]